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A PILOT STUDY TO ASSESS A PHARMACIST- AND MEDICATION 
NAVIGATOR-LED INTERVENTION TO ENHANCE ORAL CHEMOTHERAPY 
ADHERENCE 
 
MINGQIAN LIN 
ABSTRACT 
Background: Over the past 10 years, molecular-based and targeted therapies in oral 
forms have emerged and continue to change the landscape of cancer care and care 
delivery. While cancer treatments traditionally have been administered at the hospital, 
oral anti-cancer medications (OAM) can be taken by patients at the comfort and 
convenience of their homes. However, this also creates implications for ensuring that 
patients take their oral chemotherapies correctly, timely, and safely, all of which can 
impact outcomes and tolerance. Studies have shown concerning gaps in patients’ 
knowledge of taking and handling their OAM, including lower rates of adherence. 
Interventions have largely consisted of a combination of nurse- and pharmacist-led 
approaches along with the use of various educational and reminder tools. However, few 
studies have examined the potential of an intervention led by a pharmacist and a 
medication (patient) navigator. 
Objective: This ongoing pilot study aims to assess the feasibility of the intervention, the 
impact on patients’ understanding and adherence to their oral anti-cancer medications, 
and the patient perceptions of the helpfulness of the intervention. 
		 vi	
Methods: Patients who were initiating oral chemotherapy were enrolled at Tufts Medical 
Center Cancer Center, which was the study site for this pilot intervention. Study 
participants met with the Specialty Pharmacist and Medication Navigator for their initial 
education session and teach-back using the Oral Agent Teaching Tool (MOATT). They 
were also given Information Sheets and individualized Calendars for their OAM. The 
Pharmacist and/or Navigator subsequently followed up with the participants for three 
more check-ins and educational boosters. Participants completed study measures 
including the self-reported Adherence Measure, MD Anderson Symptom Inventory, and 
study evaluation. 
Results: A total of 37 patients have so far been enrolled in the study and completed their 
initial education session with the Pharmacist and 33 of those patients completed the 
Navigator-led booster check-in approximately one week later. These patients are 
receiving ongoing follow-up for their two remaining check-ins in the study. After the first 
teach-back with the Pharmacist, patients largely showed sufficient understanding of how 
to take and handle their medication. This level of understanding was sustained a week 
later at the Navigator booster. Despite high levels of self-reported adherence, patients 
showed insufficient understanding of refill logistics. Patients were highly satisfied with 
the intervention and had found both the check-ins and the educational tools provided 
useful. 
Conclusion: This Pharmacist- and Navigator-led intervention was found to be feasible to 
deliver, capable in enhancing patient understanding and adherence to their medications, 
and helpful to the patients throughout taking their OAM. 
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INTRODUCTION 
Advancements in Oral Anti-cancer Therapy  
Over the past forty years, cancer mortality rates in the United States have 
decreased by nearly 30% (SEER Cancer Statistics Review, 1975-2015). Contributions 
made by improvements in early detection and prevention as well as advancements in 
treatments have led to increasing survival among individuals diagnosed with cancer. In 
recent years, emerging new treatments have revolutionized disease management across 
several cancer types, improving disease outcomes as well as the patients’ quality of life.   
One notable example is the treatment of chronic myeloid leukemia (CML). 
Historically, treatment was limited and outcomes were grim. Options for treatment were 
primarily restricted to interferon therapy (the non-transplant treatment of choice at the 
time), hematopoietic stem cell transplantation for the few with suitable donors, or 
supportive care measures (Chopade et al. 2018). However, the introduction of tyrosine 
kinase inhibitors, first with imatinib and more recently, with other oral agents, has 
completely transformed the care of patients diagnosed with CML. These new treatments 
have led to stunning leaps in disease outcomes and have offered broader access to well-
tolerated oral therapy.   
Oral anti-cancer medications (OAM) for other cancers have also emerged, 
particularly targeted oncologics, which over the past 10 years now comprise nearly 70% 
of all oral oncologic drugs in the U.S. (IMS Institute for Healthcare Informatics 2016). In 
addition to their proven efficacy, the rise in OAM shifts the way treatments are delivered. 
While traditional, infusion-based chemotherapies are generally administered at the 
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hospital and often under direct surveillance by healthcare providers, OAM can be taken at 
home, making it more convenient for patients. 
 
Implications of Oral Anti-Cancer Medications (OAM) 
However, while these new OAM offer greater convenience for patients, there are 
also implications in considering how these treatments are administered and monitored. 
Since these oral agents are typically taken at the patients’ home, the locus of 
responsibility shifts from the medical provider(s) to the patients and their families. While 
hospital-based therapies allow the care team to monitor and promptly manage side effects 
and reactions on site, patients on oral therapies need to navigate these issues themselves, 
reaching out to their care team remotely. In addition, questions regarding the extent to 
which patients understand important instructions and precautions about their oral anti-
cancer medications become crucial to consider.  
Issues revolving around patient adherence must be properly addressed in order to 
optimize treatment efficacy and patient safety. Adherence has been defined as how 
closely or adequately patients take medications and/or follow the treatment regimen as 
prescribed by their medical providers (Osterberg et al. 2005). In an ideal scenario, a 
patient is considered fully adherent if he/she does not miss any doses and takes the 
correct amount as prescribed at the right time(s) (Foulon et al. 2011). Greater adherence 
to medication and treatment regimens has been shown to result in better outcomes (e.g., 
lower recurrence rates and better survival), as opposed to nonadherence. Conversely, 
patients with poor adherence also can sustain increased healthcare utilization, and greater 
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healthcare costs (Osterberg et al. 2005). Incorrect and/or insufficient intake of OAM may 
lead to adverse toxicities and decreased efficacy, contributing to higher hospitalization 
rates and increased morbidity and/or mortality (Ruddy et al. 2009). Studies done by 
Bhatia et al. among children with ALL (acute lymphoblastic leukemia) taking oral 6-
mercaptopurine therapy, found that decreased adherence was associated with increased 
risk of relapse (Bhatia et al. 2012). In a separate study, an adherence rate of less than 90% 
correlated with almost a four-fold increased risk of ALL recurrence in a multiracial 
cohort (Bhatia et al. 2014). Thus, how patients fare in taking their medications correctly 
and as intended, as well as how they persist in taking them potentially implicate their risk 
for adverse outcomes and suboptimal treatment response. 
 
Barriers to Patient Adherence 
Rates of adherence to OAM have been shown by various studies to be less than 
ideal with considerable variability by cancer type and drug type. One study showed that 
patients on imatinib for CML or gastrointestinal stromal tumors (GIST) have adherence 
rates of less than 80% (Al-Barrak et al. 2013). Another study found that around 30% of 
women who initiated hormonal therapy discontinued after their first prescription, while 
almost 30% of those who remained on it were non-adherent (Hershmann et al. 2011). 
Barriers to adherence have been found to be quite multifaceted and complex. One aspect 
can be due to personal characteristics of the patients. Some studies have reported that 
patients who did not take their medications attributed it to various reasons such as 
forgetting to take them, actively deciding to not follow prescribed dosages, or lacking 
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sufficient information about the medication (Osterberg et al. 2005). In a study conducted 
by Stanton-Robinson et al. among patients on antidiabetic or antihypertensive 
medications, the patients frequently expressed concern about adverse effects from 
medications (Stanton-Robinson et al. 2018). Psychological factors such as mental illness 
or cognitive deficits; emotional factors such as feeling overwhelmed by the treatment or 
prognosis; and physical factors, such as inability to read instructions or labels, or 
difficulty ingesting pills may further impede patient adherence (McCue et al. 2014).  
Barriers to adherence may also be related to inadequate physician-patient 
communication. One example is that physicians may not sufficiently explain the benefits 
and side effects of medications. Schoenthaler et al. found that patients exhibited lower 
adherence when there was less patient-provider communication, when interactions were 
not patient-centric, and when the discussions did not address sociodemographic factors 
(e.g. housing, family and partner relationships, financial status) or the medication 
regimens themselves (Schoenthaler et al. 2017).  
The degree of complexity of a treatment regimen including the overall burden of a 
regimen may also contribute to patient adherence or nonadherence. Studies have shown 
that the complexity of medication regimens (e.g., medications with complex dosing 
schedules or multi-medication regimens) is associated with lower medication adherence 
(Osterberg et al. 2005). Verma et al. recently reported in a study comparing clinical 
outcomes and medication adherence with a single fixed-dose combination treatment 
versus multi-pill-combination treatment, that patients who received single-pill or fixed 
dose combination had better outcomes that were related to better adherence (Verma et al. 
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2018). This may suggest that treatment regimens that are less complicated in their 
administration and management may be easier for patients to follow and adhere. 
Health systems and institutions may also lack adequate infrastructure and 
resources to sufficiently respond to the need for ensuring patient adherence. Absence of 
standard protocols, documentation procedures, and proper monitoring and tracking 
adherence may impede the ability and capacity of some cancer programs to identify 
issues of adherence among their patients (Greer et al. 2016). Furthermore, lack of 
professional training to provide adequate patient education on specific OAM, lack of 
developed written materials for patients, and lack of knowledge about OAM and their 
specific side effects have posed challenges for providers and institutions to sufficiently 
educate patients (Kav et al. 2008).  
 
Current Efforts to Improving Patient Adherence 
Several strategies have been tested to improve patient understanding and 
adherence to their oral medications. Programs have ranged from monitoring and 
prescribing of medications and improving institutional administration to enhancing 
patient education, patient-doctor communication, follow-up contact, and managing 
toxicities (Zerillo et al. 2018). One existing resource is a teaching guide called the Oral 
Agent Teaching Tool (MOATT) that has been created and standardized by the 
Multinational Association for Supportive Care in Cancer for clinical and research use to 
aid healthcare providers in enhancing patient education (Kav et al. 2009). 
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Tools and devices also have been developed for patients to further enhance self-
management strategies. Reminder tools, such as pill boxes or electronic messaging, have 
been provided for patients who have reported challenges remembering to take 
medications. Calendars, schedules, and charts are examples of tools that have been 
created to help patients stay organized and to remind them to take their medications, 
especially for those with treatment regimens consisting of multiple drugs (McCue et al. 
2014). Additional studies have indicated that overall, enhanced patient education, 
increased monitoring, regular patient check-ins, and multi-component interventions have 
resulted in improved patient adherence (Zerillo et al. 2018). 
To date, many interventions designed to improved medication adherence have 
been led by pharmacists and/or nurses and have been implemented in multi-faceted 
approaches and across disease groups. Pharmacist-led initiatives have involved the 
pharmacists checking accuracy of prescriptions (Mancini et al. 2012). Others have 
featured pharmacy models integrated within oncology practices (Muluneh et al. 2018) 
and directed more individualized education and follow-up (Lee et al. 2006), which have 
shown promising results in increasing patient understanding of medications, high patient 
satisfaction, and improvements in adherence. Adherence initiatives led by nurses have 
similarly focused on improving patient education and medication management, including 
management of symptoms and adverse effects. One intervention among adult patients 
receiving new oral anti-cancer agents involved having a nurse meeting or calling patients 
by phone within the first week, providing standard chemotherapy education, and 
following up with regular phone calls found that the intervention group had higher 
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adherence rates than those in the control group (Schneider et al. 2014). Interestingly, a 
hybrid model consisting of a nurse and pharmacist team approach intervention 
investigated by Berry et al. for inpatient oncology patients found that there was better 
medication understanding (drug name, dose, route of administration and frequency) after 
discharge by providing patients with written instructions, giving them an educational 
session at time of discharge, and calling them post-discharge for knowledge 
reinforcement (Berry et al. 2014).  
 
Patient Navigators as an Extension of the Care Team 
 The current literature suggest that interventions that involve professional guidance 
in educating patients about OAM and addressing side effects, as well as a systematic way 
of following up with patients can be quite effective in improving adherence. While 
healthcare professionals such as nurses and pharmacists have been deployed to educating 
patients and checking in with them periodically, this expansion of their roles also comes 
with the challenges of limited capacity.  
One potential solution is to introduce lay navigators as an extension to the care 
team in providing ongoing support for patients and to extend the care team’s capacity.  
Patient navigation has been utilized as a way to improve patient experience and reduce 
barriers of care access and the time to diagnosis, particularly among vulnerable patient 
populations. There is also growing literature proposing it as a potential approach to 
improve patient adherence. A study evaluating the impact of the Breast Oncology 
Navigation Program at a public hospital in New York City showed that patient navigators 
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at the site did improve adherence with follow-up and adjuvant therapy as well as 
timeliness to care among their patients who identified as ethnic minorities (Castaldi et al. 
2016). 
In 2014, a patient navigation program was created at Tufts Medical Center Cancer 
Center, located in Boston’s Chinatown, to assist patients of lower socioeconomic status 
and/or of Chinese origin in navigating the healthcare system while receiving active 
cancer treatment. As the navigators provided linguistically and culturally congruent 
support, they also ultimately became embedded within the clinical team. Frequently, the 
navigators served as “medical liaisons,” identifying and addressing issues directly 
pertinent to the patients’ clinical care. In working with the patients, the oncology 
providers and the on-site specialty pharmacist, the navigators identified concerns 
regarding improper intake and/or suboptimal understanding about medications, and 
worked with the clinical care team to address these concerns. The successful integration 
of the lay patient navigators into the cancer care team suggests that they could be useful 
in providing an extension of the providers’ roles in caring for their patients, expanding 
their system of support. 
 
Specific Aims: 
Studies have shown that overall there is a risk for patients to have subpar 
understanding and knowledge as well as substandard adherence to prescribed oral anti-
cancer medications. Current interventions have evaluated the use of various tools and the 
implementation of nurse-led or pharmacist-led follow-ups to minimize this risk. 
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However, further work is needed to investigate how these interventions can be best 
operationalized and what the optimal method(s) are to support patients in elevating their 
understanding and adherence to their oral treatment regimens.  
Therefore, a pilot longitudinal study was designed to improve education and 
support, adherence, and safety for patients starting on OAM in a hospital-based cancer 
program. While much of current research has involved the use of nurses, pharmacists, or 
a hybrid of both in interventions to improve medication adherence, this is the first to our 
knowledge to implement an initiative jointly-led by an oncology-specialty pharmacist and 
a lay navigator. To assist patients on issues related to OAM and work with the pharmacist 
to provide tailored, longitudinal support for these patients, the role of a “Medication 
Navigator” was created.  
The purpose of the intervention was to enhance education and support for patients 
who were newly prescribed OAM(s), particularly among vulnerable populations (i.e., 
non-English, lower socioeconomic status, elderly). Thus, the three-fold goals of this 
paper are: first, to describe the feasibility of the intervention through metrics of 
enrollment and follow-up, team personnel availability, and mode of patient contact; 
second, to describe the impact of the educational teaching sessions and check-ins on 
patients’ understanding and adherence to their oral medications; third, to describe the 
feedback about the study gathered from the patient participants on their perceived 
usefulness of the check-in sessions and the instrumental tools provided as part of 
intervention design.  
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METHODS  
Research setting and staff 
Study participants were identified and enrolled in the hematologic malignancy 
and solid tumor clinic at the Cancer Center at Tufts Medical Center, a large urban 
academic hospital located in downtown Boston, Massachusetts, which served as the study 
site. A pharmacy was physically located at the clinic as part of an integrated system, as 
well as an on-site pharmacist specialized in oncology care. The Specialty Pharmacist 
aimed to fulfill multiple roles in the care team. First, he worked with the oncology team 
in providing in-depth education on prescribed medications, particularly anti-cancer drugs. 
Second, he worked with the pharmacy administration to check for and obtain insurance 
prior-authorizations, as well as look for any financial assistance programs available to 
help patients receive treatment. Third, he reviewed prescriptions to ensure safety and 
accuracy prior to dispense.  
The role of a “Medication Navigator” was also recently created around the time of 
the study and grew from the experiences the Cancer Center’s patient navigators had in 
assisting patients on an increasing number of medication-related issues. The Medication 
Navigator received training from the Specialty Pharmacist in these issues. The role of the 
Medication Navigator was an extension of the professional care team, providing ongoing 
support for patients at planned intervals and serving as another line of communication to 
patients’ care teams.  
	11 
The study received approval from the Tufts Medical Center Institutional Review 
Board (IRB) to be conducted at this site. Hematology/oncology providers at the Cancer 
Center were also notified by the study team to elicit their support.  
 
Study participants – Screening and Consent 
 Potentially eligible patients were identified through the Specialty Pharmacist, who 
was notified by the oncology team of patients that were newly prescribed a new regimen 
including at least one OAM.  Eligible patients were invited to participate in the study if 
they had an active diagnosis of a solid tumor or hematologic malignancy, were at least 18 
years of age, were proficient in English or spoken Chinese, and were receiving their 
primary adult hematology/oncology care at Tufts Cancer Center. Patients who had been 
taking newly prescribed OAM for more than 7 days upon screening were excluded from 
the study.  
 Upon identifying a patient who was eligible for the study, the Specialty 
Pharmacist and the Medication Navigator planned for an initial education session on or 
close to the treatment start date to review specific information about the OAM(s). 
Together, they prepared an Information Sheet about the OAM as well as an 
individualized Medication Calendar. Both of these tools were created to enhance patient 
understanding and support.  
The Specialty Pharmacist and Medication Navigator approached patients in clinic 
typically after their clinic visits or in the Infusion Center where they were monitored for 
(and in some cases administered) their first dose of oral chemotherapy. Before providing 
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informed consent for study participation, patients were offered the initial education 
session with the Specialty Pharmacist and Medication Navigator to review specific 
information about the medication as part of standard of care. This initial meeting was 
offered to all patients regardless of their decision to participate in the study. All patients 
were provided a Medication Calendar to help them keep track of taking their medications 
and an Information Sheet that included important information about the medication 
taking and management. During the education session, the Pharmacist discussed each 
part of the Information Sheet and the Calendar, using them as instructional aids and as a 
way to show how the patient may use these tools on their own. 
Following the initial education session, informed consent was obtained from 
patients who were interested in participating in the study, which involved three additional 
check-in sessions following the initial meeting, and the completion of questionnaires 
assessing their understanding of and adherence to medication, symptom burden, and 
overall feedback about the initiative. 
 Given Tufts Medical Center’s unique location in Boston’s Chinatown, the 
hospital serves a large number of Chinese and/or (non-English)-speaking patients.  To 
accommodate for Chinese participants who did not speak English fluently, all study 
measures including consent forms, the modified MOATT education teach-back scripts, 
the Medication Information Sheets, and Medication Calendar were translated into both 
Traditional and Simplified Chinese versions; following professional translation, the IRB 
approved their use. The Medication Navigator on staff was fluent in Cantonese- and 
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Mandarin- Chinese and was able to converse and review all study forms with any 
Chinese-speaking participants. 
 
Procedure 
The structure of the study as a longitudinal intervention consisted of a total of four 
meetings or check-ins with the enrolled patients through their first and second oral 
chemotherapy cycles or refills.  Scheduled check-ins were conducted by the Specialty 
Pharmacist and/or Medication Navigator either in person or over the phone. In-person 
check-ins were typically coordinated with the patient’s scheduled clinic visits. If 
scheduled clinic visits were not anticipated within the study windows or if the patients 
expressed preference, the study participants were contacted by phone.   
Two of these check-ins served as educational sessions, led by the Specialty 
Pharmacist, while the other two served as interval check-ins done by the Navigator to 
further reinforce the level of understanding about the medication as well as to address any 
questions or issues the patient had.  
An overview of the four sessions is illustrated in the schema below with the 
allowable windows around each assessment.  
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 Pharmacist-
Led Teach-
back 
(Time 1) 
Navigator 
Booster  
(Time 2) 
 
Pharmacist-
Led Teach-
back  
(Time 3) 
 
Final 
Navigator 
Booster  
(Time 4) 
Time windows Start of new 
OAM 
7 days (+/- 3) 
after Time 1 
Start of Cycle 2 
of medication, 
or date of first 
refill 
7-28 clinic days 
after Time 3, or 
before start of 
Cycle 3 or 
second refill. 
Mode of 
contact 
In person In person or 
phone 
In person or 
phone 
In person or 
phone 
Check-in 
attendees 
Participant, 
Medication 
Navigator, 
Specialty 
Pharmacist 
Participant, 
Medication 
Navigator 
Participant, 
Medication 
Navigator, 
Specialty 
Pharmacist 
Participant, 
Medication 
Navigator 
Modified 
MOATT 
Teach-back 
X X X X 
Adherence 
Measure 
 X X X 
Demographics 
Form 
X    
Study 
Evaluation 
 X  X 
MD Anderson 
Symptom 
Inventory 
X X (in person 
only) 
X (in person 
only) 
X (in person 
only) 
Abbreviations: MOATT (Multinational Association for Supportive Care in 
Cancer’s Oral Agent Teaching Tool)  
 
Time 1: Initial Education Meeting and Teach-back 
Time 1 was designated as the initial education session led by the Pharmacist 
followed by patient teach-back. Per study design, this was always conducted in person. 
This was planned on the date on which the patient started taking the newly prescribed 
OAM. During Time 1, the Pharmacist guided the patient through the Information Sheet 
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and Medication Calendar of the prescribed oral chemotherapy, teaching the patient what 
the medication was, when to take it, how to properly take it, and how to properly handle, 
store, and dispose of it. The Pharmacist then went through a modified version of the 
MOATT patient teach-back, a formal method of assessing how well the patient 
understands information about their medication(s) that was shared with them. To end the 
session, the Medication Navigator administered the Demographics Form and the MD 
Anderson Symptom Inventory to patients who provided consent to study participation. 
Study measures were selected to assess symptoms at baseline. The study team was 
notified of any clinical issues that needed to be promptly addressed.  
 
Time 2: Cycle 1 Medication Navigator Check-In 
The second check-in, “Time 2,” was scheduled to be 1 week (+/- 3 days) after the 
initial meeting. This check-in was an individual meeting between the participant and the 
Medication Navigator, and served as an opportunity to review any concerns or issues, 
and/or to reinforce education and knowledge about the anti-cancer medication. The 
Medication Navigator completed the patient teach-back and the verbal responses were 
recorded. If this was conducted in-person, participants also completed the Adherence to 
OAM measure, MD Anderson Symptom Inventory, and the initial study evaluation. If 
done over the phone, the Medication Navigator administered only the Adherence to 
OAM measure and recorded the responses, and another trained study staff administered 
the study evaluation to preserve the integrity of responses. The Symptom Inventory was 
not administered over the phone to reduce responder burden. 
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Time 3: Cycle 2 Start – Pharmacist Education Booster 
“Time 3” was scheduled around the time when participants started on Cycle 2 of 
the oral chemotherapy regimen or picked up the first refill of the medication. This check-
in served as a “booster” education session led by the Pharmacist as an opportunity to 
reinforce specific information about the oral chemotherapy. This meeting involved the 
participant, Pharmacist, and Medication Navigator. If done in person, the Pharmacist 
administered the patient teach-back and the Medication Navigator administered the 
Symptom Inventory and Adherence Measure. As with Time 2, if this assessment was 
completed by phone, the Symptom Inventory was not administered. 
 
Time 4: Cycle 2 Medication Navigator Final Check-in 
The last check-in was planned for after the first week of Cycle 2 until before the 
start of Cycle 3. “Time 4” consisted of a one-on-one meeting between the Medication 
Navigator and the participant. The same measures and patient teach-back were completed 
as in previous check-ins, either in person or over the phone. A final study evaluation was 
given to participants at the conclusion of their participation in the study. 
 
Study Forms and Collection Measures 
Study measures were administered by a study team member to participants either 
in-person or over the phone. All forms were translated into Simplified and Traditional 
Chinese and subsequently approved by the IRB. 
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Medication Information Sheets 
 Drug Information Sheets were adapted from the Michigan Oncology Quality 
Consortium and provided to participants upon starting on treatment. Information Sheets 
were translated into Traditional and Simplified Chinese for 12 of the more commonly 
prescribed OAM at the study site. They included instructions on medication taking and 
handing, most notable side effects associated with the medication, and contact 
information for whom to get in touch for emergency and non-emergency concerns.  
 
Demographics Form 
 Upon study entry, participants completed the Demographics form, which 
collected information about their year of birth, gender, race/ethnicity, education, 
employment, and healthcare costs/insurance status.  
 
Patient Teach-back (modified MASCC Oral Agent Teaching Tool – MOATT) 
A modified version of the Oral Agent Teaching Tool was used to ask the 
participant questions to assess their knowledge of his/her medication(s), their ability and 
understanding to take and handle the medication, and understanding about drug-specific 
information such as dose and schedule, side effects, and interactions with foods and 
drugs. Question stems from the original version were tailored to the flow of the session 
conversation and were adapted into a script form. Evaluation options such as “Correctly 
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answered,” “Correctly answered with use of tools/required prompting,” and “Incorrectly 
answered” were added to each question. 
 
Self-Reported Adherence to Oral Anti-Cancer Medication (OAM) Measure 
 This measure included 6-13 questions about the participant’s adherence to the oral 
chemotherapy medication, assessing self-reports on how the participant has been taking 
it, how well it has been taken, and how often it is refilled. Participants who were taking 
more than one medication completed one form for each medication, separately, as 
different medications have unique ways of administration and management. Three 
questions were modified from a 3-item validated medication adherence measure, 
previously used with patients with HIV (Wilson et al. 2016).  
 
MD Anderson Symptom Inventory 
 The MD Anderson Symptom Inventory (MDASI) is a validated, multi-symptom 
patient-reported outcome measure that assesses symptoms caused by the cancer or 
treatment (Cleeland et al. 2000). It included 13 core items that encompassed symptoms 
presented with the highest frequency and/or severity in patients with various cancers on 
different treatments. Some of these symptoms included pain, fatigue, nausea, emotional 
distress, and lack of appetite. Six other items asked about how the symptoms interfere 
with how the patient felt and functioned (general activity, mood, walking ability, normal 
work, relationships, enjoyment of life). All items referred to the prior 24 hours and were 
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rated on a 0-10 scale (0 being not existent, 10 being most severe). This tool, administered 
at each in-person assessment, was already available and validated in written Chinese. 
 
Study Evaluation 
 The study evaluation obtained the participant’s thoughts on the usefulness of the 
check-ins and study tools (i.e., Medication Information Sheets and the Calendar). It 
consisted of 9-14 questions and, as with all study materials, was translated into 
Traditional and Simplified Chinese. Two separate evaluation forms were created: an 
initial evaluation given at the Cycle 1 Navigator check-in (Time 2), to obtain the 
participants’ initial thoughts on the study and usage of the Information Sheet and 
Calendar; and a final evaluation given at the Cycle 2 Navigator check-in (Time 4) to 
gather their feedback on the check-ins during Cycle 2, their usage of the Information 
Sheet and Calendar during Cycle 2, as well as the study overall. 
 
Medical Chart Review Form 
 The medical chart review form was completed by trained study staff and centrally 
reviewed by the study oncologist. Data included information on disease characteristics 
including cancer diagnosis, year of diagnosis, comorbidities requiring medication 
management, and treatment history. For the purposes of this study in terms of medication 
management, the definition of comorbidity was considered more broadly than what is 
included in the Charlson Comorbidity Index, a scale that is typically used to predict 10-
year survival in patients with comorbidities (Charlson et al. 1987). Included in the study 
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definition were conditions such as hypertension that required long-term management with 
medications for certain patients, which would potentially add to overall medication 
burden. 
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RESULTS 
An Overview of Study Enrollment 
 
 Study recruitment began in September 2018. Figure 1 illustrates the progress on 
enrollment and completion of the participants through the study as of February 2019. 
Fifty patients were found to be eligible for study enrollment, 11 of whom were not 
approached during the eligible period. Reasons for not being approached included: 1) 
three patients missed due to workflow (e.g. clinic visits extended past schedule, study 
team not being notified in time to prepare); 2) seven missed due to Pharmacist 
unavailability for the initial education session; and 3) one patient was unable to come to 
the study site for the first visit with the Pharmacist and Navigator due to logistical 
challenges. Of the 39 who were approached by the study team, two had refused 
participation (5% refusal rate).  
 Thirty-seven patients received the initial education and teach-back and completed 
all study measures at the time of enrollment (Time 1). Subsequently, the Medication 
Navigator was able to contact and/or meet with 33 patients for the Time 2 booster check-
in approximately a week after initiating treatment, while 3 patients could not be reached 
and 1 patient withdrew from the study. These 33 patients would receive further follow-up 
by the Pharmacist and Navigator (Time 3 and Time 4) past their first medication refill 
and into their Cycle 2 treatment. 
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Figure 1: Study Enrollment and Completion.  
 
Description of the Study Population 
 The descriptive variables of the study population are displayed in Table 2. Among 
the 37 patients enrolled, 51.3% were male, the median age was 65 years old and the 
interquartile range (quartile [Q] 3-Q1) was 17 years. While 62.2% self-identified as 
White, about a quarter of the patients were of Asian origin (27.0%). Of note, eight out of 
the 10 Asian patients spoke Chinese only, with limited to no proficiency in English. The 
Eligible Patients (n=50) 
Patients Enrolled and Completed Pharmacist 
Teach-back  
(Time 1) (n=37) 
Completed Navigator Booster (Time 2) (n=33) 
Refused (n=2) 
Missed (n=3) 
Withdrawn (n=1) 
Not enrolled 
(n=11) 
Ongoing evaluation 
(Time 3 and Time 4) 
Main Reasons: 
• Study team 
unavailability 
• Logistical 
challenges for 
patients 
• Workflow 
barriers 
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majority of the patients had completed some college (62.2%) and slightly over half of the 
patients (58.3%) had no paid employment at the time of the study. About half of the 
patients had some form of subsidized insurance (e.g. Medicare, Medicaid), and 86.5% of 
the patients reported that their insurance plans “Usually” or “Always” covered their 
healthcare services. When asked if whether their cancer care had caused any financial 
challenges for them or their families, 66.7% of the patients reported that they had not 
experienced any. 
 Disease characteristics are summarized on Table 2. Almost 60% of patients had 
hematologic cancers, while the remainder had solid tumors (40.5%). Among the 
diagnoses that could be staged using standard criteria, 63.6% were considered advanced 
stage (stage IV) cancers. The median number of years since their cancer diagnoses was 
2.0. The purpose of the newly prescribed OAM was for second line treatment in oral 
(70.3%), such as in cases of cancer relapse or progression, rather than as first-line 
treatment (29.7%). Additionally, 64.9% had a chronic health condition requiring 
medication management with a median of two medications.  
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Table 2: Baseline Personal and Disease Characteristics.  
Variable Total Sample (n=37) 
Female – no. (%)  18 (48.7) 
Age – years (Q1, Q3) 
     Median 
 
65 (54, 71) 
Race/ethnicity – no. (%)  
     White 
     Asian 
     All other 
 
23 (62.2) 
10 (27.0) 
4 (10.8) 
Highest level of education – no. (%)  
     Less than high school 
     High school graduate 
     Some college or higher 
 
8 (21.6) 
6 (16.2) 
23 (62.2) 
Employment – no. (%)   * 
     Paying job 
     No paying job 
 
15 (41.7) 
21 (58.3) 
Insurance type – no. (%)  
     Subsidized 
     Unsubsidized 
 
18 (48.6) 
19 (51.4) 
Cancer type – no. (%)  
     Solid tumor 
     Hematologic malignancy 
 
15 (40.5) 
22 (59.5) 
Years since diagnosis – no.  
     Median (Q1, Q3) 
 
2.0 (0, 9) 
Purpose of medication in management of 
current disease – no. (%)  
     Frontline 
     Change of regimen 
 
 
11 (29.7) 
26 (70.3) 
Any comorbidities requiring medication 
management – no. (%)  
     Yes 
     No 
 
 
24 (64.9) 
13 (35.1) 
*One patient did not respond to this question. Q, quartile. Q1,Q3 refers to the 
interquartile range (Q3-Q1).  
 
Personnel Availability and Mode of Contact with Study Participants 
 Pharmacist and Medication Navigator attendance and how they contacted the 
patients were tracked at Time 1 and Time 2. During the initial education session (Time 
1), ideally both the Pharmacist and Medication Navigator would be present for 100% of 
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the meetings. In actuality, 33 of the 37 patients (89.2%) met with both study team 
members present. The other 4 patients met with the Pharmacist only due to logistical or 
workflow reasons in the clinic. During the Navigator booster check-ins at Time 2, all 
patients met with the Navigator as per study design. The Navigator met with 22 patients 
(66.7%, n=37) in person and conducted the session over the phone with 11 patients 
(33.3%, n=33). All patients received study tools and where appropriate, received them in 
Chinese.  
 
Assessing Patient Understanding of Medication Taking, Handling, and Refilling 
 At each teach-back session, the Pharmacist or Navigator asked the patients 
questions about how to take their OAM, how to handle/store them, and where to fill their 
prescriptions. Patients were encouraged to refer to their tools (Information Sheets and 
Medication Calendar) to answer the teach-back questions. The assessments of the 
patients’ responses are displayed in Table 3. At Time 1, most study participants were able 
to name their OAM correctly either from memory (46.0%, n=37) or with the use of the 
Information Sheets and/or the Medication Calendar (51.3%, n=37). Similarly, at Time 2, 
81.8% (n=33) of patients were able to recall the names of their medications. However, 
18.2% of patients (n=33) could not remember the name or pronounce it correctly, or 
named it incorrectly. 
At Time 1, when asked when the medication should be taken, 32 of the 37 
patients (86.5%) were able to answer correctly and five patients (13.5%) answered it with 
the use of the tools. None of the patients answered incorrectly. At Time 2, 32 patients 
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(97.0%, n=33) were able to correctly describe when to take their medications. One patient 
was not asked this question because at the time of the check-in, the medication was on 
hold. Patients were also asked how they should take their OAM and specifically whether 
or not it should be taken with food. At Time 1, 94.6% of patients (n=37) answered 
correctly while 5.4%  answered incorrectly. At Time 2, 97.0% of patients (n=33) 
answered correctly and no patients answered incorrectly. Like the previous question, the 
patient with the medication on hold was not asked this question per study design. 
During the initial Pharmacist teach-back, 89.2% of the patients correctly 
described how to store the medication, 8.1% correctly answered upon referring to their 
tools, and 2.7% answered incorrectly (n=37). In comparison, during the Navigator 
booster check-in, all patients (excluding the one patient with the medication on hold) 
answered correctly. 
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Table 3: Patient Recall and Understanding of Medication Management.  
Assessment Item Pharmacist-Led 
Teach-back  
(Time 1) – no. 
(%) 
N=37 
Navigator-Led 
Booster  
(Time 2) – no. 
(%) 
N=33  
What is the name of the medication being taken? 
     Correct 
     Correct, with use of tools 
     Incorrect 
 
17 (46.0) 
19 (51.3)   
1 (2.7)  
 
23 (69.7) 
4 (12.1)  
6 (18.2)  
When should you take the medication? 
     Correct 
     Correct, with use of tools 
     Incorrect 
     Not applicable (medication on hold) 
 
32 (86.5) 
5 (13.5)  
0  
0 
 
32 (97.0) 
0  
0  
1 (3.0) 
How should you take the medication (Does it 
matter if you take it with food or not?) 
     Correct 
     Correct, with use of tools 
     Incorrect 
     Not applicable (medication on hold) 
 
 
35 (94.6) 
0  
2 (5.4)  
0 
 
 
32 (97.0) 
0  
0  
1 (3.0) 
How should you store the medication? (Where 
do you keep your medication?) 
     Correct 
     Correct, with use of tools 
     Incorrect 
     Not applicable (medication on hold) 
 
 
33 (89.2) 
3 (8.1)  
1 (2.7)  
0 
 
 
32 (97)      
0  
0  
1 (3.0) 
 
Understanding the Extent of Patient Support 
 Patients were asked as part of the initial teaching session about their support 
system outside of the hospital in helping them manage their medications (Table 4). About 
40% of patients (n=37) reported having someone at home to help them take their 
medications. Additionally, patients were asked during the teach-back about when and 
who to call if certain scenarios (e.g., side effects, issues with getting medications, health 
emergencies) came up. All patients were able to elaborate on at least one major scenario 
that was discussed during the teaching session, either from their memory or by referring 
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to their Information Sheets and/or Medication Calendars. Most patients (91.9%, n=37) 
were able to identify whom they should contact on their cancer care team for any 
problems or concerns. 
 To recognize the potential for questions or issues to occur in between hospital 
visits, patients were also asked during the Navigator booster if they had contacted anyone 
on their care team with concerns between Time 1 and Time 2 (Table 4). About two-thirds 
of the patients (n=33) reported that they did not have any issues that prompted them to 
reach out to their care teams. Those who did reach out to the care team had concerns such 
as side effects from the medication or missing doses. One patient contacted the care team 
about having difficulty swallowing, and the team helped arrange for him to take the 
medications in applesauce. Another patient actively reached out informing her oncologist 
that she accidentally took 2 pills of her oral chemotherapy instead of one. 
Similarly, instances where the Pharmacist or the Navigator reached out to 
someone on the care team on behalf of the patients were also documented. During the 
initial Pharmacist teach-back session, the Pharmacist had reached out to another oncology 
provider regarding concerns shared by 12 patients (32.4%, n=37), and managed to help 
resolve any issues at the time of the check-in for 18 patients (48.7%, n=37). Some issues 
that arose from that initial session included navigating the prescription fill process, 
monthly copayments for the medication, concerns about medication tolerance, drug 
interactions with other prescribed medications (for symptom management), and difficulty 
with swallowing pills. In one example, at the initial meeting, the Pharmacist identified a 
discrepancy between the medication label instructions and the doses that were ordered. 
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He was able to promptly work with the patient’s nurse practitioner and clarify the dosing 
schedule that was unique to the patient’s treatment plan and that would be different from 
the standard instructions for that medication. He was then able to thoroughly explain this 
to the patient and clarify details of the treatment plan. 
In comparison, during the Time 2 booster check-in, the Navigator ended up 
reaching out to the care team for issues brought forth by 20 patients (60.6%, n=33) and 
was able to address any concerns at the check-in for 6 patients (18.2%, n=33). Some 
examples of questions and concerns identified during the Navigator check-in were: 
symptoms and side effects, uncertainty over where to get refills, diet adjustments and 
taking nutritional supplements, logistics of upcoming clinic appointments, and overall 
questions about disease prognosis and the future treatment plan. The Navigator also 
encountered culturally sensitive issues raised by some Chinese-speaking patients. One 
Chinese-speaking patient was worried and hesitant to start her second treatment cycle 
around the Chinese Lunar New Year because it was considered “bad luck” (especially on 
the first day of the New Year) and also because she was experiencing some symptoms 
from the previous cycle. She had just told her care team of the latter concern, fearing that 
they would not understand the greater cultural relevance. The Navigator was able to 
discuss this with the Pharmacist and the care team and the patient and her team agreed 
upon a plan to resume treatment after the Chinese New Year.  
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Table 4: Medication Support and Help-seeking.  
 
How Patients Perceived the Usefulness of the Study 
 At the end of Time 2, patients were invited to provide feedback on the two 
meetings with the Pharmacist and Navigator as well as the Medication Information 
Sheets and Medication Calendar provided to them at the beginning of the study. The 
results of the feedback variables are described in Table 5. Nearly all patients (90.9%, 
n=33) thought the initial meeting was “Very helpful” when they first received their oral 
chemotherapy medications. Most patients (94.0%, n=33) also found the subsequent 
check-in with the Navigator to be “Very helpful.”  
Assessment Item Pharmacist-
Led Teach-
back  
(Time 1)  – no. 
(%)  
N=37 
Navigator-
Led 
Booster  
(Time 2) – 
no. (%)  
N=33 
Does anyone at home help you with any of your 
medication taking? 
     Yes 
     No 
 
 
15 (40.5) 
22 (59.5) 
N/A 
When should you call cancer care team (scenarios)? 
    Recalled at least 1 major scenario 
    Recalled at least 1 major scenario, with use of tools 
    Unable to recall any scenarios 
 
34 (91.9) 
3 (8.1) 
0 
N/A 
 
 
 
Who should you call for any problems? 
     Able to identify 
     Unable to identify 
 
34 (91.9) 
3 (8.1) 
N/A 
Has the patient contacted anyone with concerns since 
the first meeting with the Pharmacist and Navigator? 
     Yes 
     No 
N/A  
 
11 (33.3) 
22 (66.7) 
Did the Pharmacist/Navigator contact anyone on the 
care team at the time of the check-in? 
     Yes 
     No, issues resolved at check-in 
     No issues raised 
 
 
12 (32.4) 
18 (48.7) 
7 (18.9) 
 
 
20 (60.6) 
6 (18.2) 
7 (21.2) 
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 Patients who used the tools were further asked about how frequently they used 
them and which parts of the tools they most often used. About 80% of patients reported 
that they used the Information Sheets. The section in the Information Sheets on potential 
side effects was most widely read. However, almost 20% of the patients did not use them 
at all. Some of these patients felt that they were quite complex and verbose, making it 
difficult to understand with the much of the medical jargon.  
With regards to the Medication Calendar, about 70% of patients reported that they 
used it to remind them to take their medications. The remaining 30% of patients did not 
use the Calendar at all. Among these patients, some shared that they did not feel the 
Calendar was necessary due to the “simplicity” of their treatment (eg., take one pill a day 
in the morning) and therefore it was “easy to remember.” Other patients did not use it 
because they adapted the tool into their electronic calendars (eg., phone, computer). The 
feature of the Calendar that was most widely used was the checkboxes on each day to 
mark when the medication(s) were taken. Approximately a third of the patients also used 
the extra blank calendar that was provided to them to write down notes, questions, and 
any side effects they had experienced. When asked how helpful they found the 
Information Sheets and the Medication Calendar to be, 72.7% of patients thought the 
Information Sheets were “Very helpful” and 75.7% of patients found the Calendars to be 
“Very helpful” (n=33). 
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Table 5: Patient Acceptability and Feedback on Helpfulness of Intervention.  
Patient-reported Feedback Variables Evaluation (Time 
2) – no. (%) 
N=33 
Meeting with Specialty Pharmacist and Medication Navigator upon 
getting the medication 
     Very helpful 
     Somewhat helpful 
     Not at all helpful 
 
 
30 (90.9) 
2 (6.1) 
1 (3.0) 
Check-in with Medication Navigator 
     Very helpful 
     Somewhat helpful 
     Not at all helpful 
 
31 (94.0) 
1 (3.0) 
1 (3.0) 
How often did you use the Medication Drug Information Sheet(s)? 
     Daily 
     Weekly 
     Other frequency 
     Did not use 
 
11 (33.3) 
5 (15.2) 
11 (33.3) 
6 (18.2) 
If you used the Information Sheet, which parts did you use? (Check 
all that apply) 
     Side Effect Summary 
     About Your Medication 
     How to Take Your Medication 
     What Foods and Drugs May Interact 
     Important Precautions 
     Who to Call with Questions 
     Storage, Handling, and Disposal 
 
 
23 (69.7) 
19 (57.6) 
17 (51.5) 
17 (51.5) 
16 (48.5) 
16 (48.5) 
15 (45.5) 
How often did you use the Medication Calendar? 
     Daily 
     Weekly 
     Other 
     Did not use 
 
13 (39.3) 
5 (15.2) 
5 (15.2) 
10 (30.3) 
If you used the Calendar, which parts did you use? (Check all that 
apply) 
     Checkboxes to mark when medication was taken 
     Blank calendar for notes 
     Medication(s) listed 
     Written dosage explanations 
 
 
20 (60.6) 
10 (30.3) 
9 (27.3) 
8 (24.2) 
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The Patients’ Self-Reported Adherence 
Table 6 presents the results of patients’ self-reported adherence. Most patients 
reported that they did an “Excellent” job at taking their medications and “Always” took 
them the way they were supposed to. The majority of patients (87.9%, n=33) initiated 
their oral treatment on the planned day, whereas four experienced a delay due to 
prescription-related factors.  
The Pharmacist also evaluated the free-text, written patient responses as part of 
the Adherence measure. Upon comparing their responses and the actual instructions for 
taking their respective medications, all 33 patients responded correctly. However, when 
patients were asked how often they were to fill their medications, 24.2% of them were 
unable to correctly answer. Patients were also asked where they would get their first 
refills for their medications. Of the 33 patients who attended the Navigator booster, 
nearly a quarter of them either did not know where to get their refills or answered 
incorrectly (e.g., provided a the name of the wrong pharmacy).  
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Table 6: Patient Self-reported Adherence.  
 			
Assessment Item Navigator-Led 
Booster (Time 2) 
– no. (%)  
N=33 
Patient-Reported 
Since you first started taking this medication, how good a job did 
you do at taking it in the way you were supposed to? 
     Poor 
     Fair 
     Good 
     Very good 
     Excellent 
 
 
0 
1 (3.0) 
4 (12.0) 
10 (30.3) 
18 (54.6) 
Since you first started taking this medication, how often did you 
take it in the way you were supposed to? 
     Rarely 
     Sometimes 
     Usually 
     Almost always 
     Always 
 
 
0 
0 
2 (6.0) 
3 (9.1) 
28 (84.9) 
Pharmacist-Verified 
When did you first start taking this medication? 
     As planned/on the instructed day 
     Experienced unintended delays  
 
29 (87.9) 
4 (12.1) 
On days and weeks when you take this medication, how often are 
you supposed to take it? 
     Correctly answered 
     Incorrectly answered 
 
 
33 (100) 
0 
How often are you supposed to fill this medication? 
     Correctly answered 
     Incorrectly answered 
 
25 (75.8) 
8 (24.2) 
Where will you fill your prescription for Cycle 2? 
     Correctly  
     Incorrectly  
     Patient unsure 
     Not applicable (no plan in place) 
 
22 (66.7) 
1 (3.0) 
7 (21.2) 
3 (9.1) 
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DISCUSSION 	 		 Studies have highlighted the striking gaps in adherence and understanding among 
patients taking oral medications, including OAM. A variety of interventions have been 
implemented with the goal of reducing rates of non-adherence, while improving patients’ 
knowledge of managing their medications. We sought to extend the capacities of 
oncology teams and improve the support for patients on OAM through a Pharmacist- and 
Medication Navigator-led intervention. 
 
The Feasibility and Scalability of the Intervention 
 One goal of this analysis was to determine if patients who were starting on OAM 
could be provided with teaching sessions, regular check-ins, and patient tools 
(Information Sheets and Calendar), and whether or not these could be carried out by the 
Pharmacist and Medication Navigator in a timely fashion relative to the initiation of the 
OAM. A metric used to determine this was whether the Pharmacist was available to lead 
the initial teach-back session when the patients were starting treatment. While the 
Pharmacist was able to meet with the majority of the patients (78%), our results indicate 
the need to further address logistical barriers in terms of capacity and workflow. Effective 
communication between the clinical providers and the Pharmacist in identifying potential 
starts on OAM ahead of time could allow more time to plan for the teaching session and 
to prepare the Information Sheets and Medication Calendars that are personalized for 
each patient. Another strategy could be to more systematically introduce hand-off 
between the provider and the Pharmacist-Navigator and initiate the first educational 
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session as a planned, sequential visit after the patient’s clinic visit. This could also further 
integrate this initiative into routine clinical care. Alternatively, to address logistical 
challenges for patients to physically attend the in-person visits, conducting the initial 
teach-back through other communication methods such as online video or by phone could 
be explored. This could be potentially helpful for patients who live in remote 
geographical areas or face other challenges for them to travel to the hospital. 
 The Medication Navigator was also quite successful in contacting patients for 
their booster check-ins approximately a week after starting treatment. In-person meetings 
at the hospital and phone calls appeared to both be plausible ways to reach patients for 
their check-ins. This suggests that there is flexibility in checking in with patients through 
different channels of communication without necessarily compromising the content of the 
check-ins.  
 Medication Calendars were also created for every patient enrolled in the study, 
each personalized to the patient’s individual medications and treatment plan. The 
incorporation of this tool into this intervention and the ability to also provide translated 
versions for all Chinese-speaking patients indicates that it is possible to extend this to all 
other (non-English speaking) patients in the future. 
 
The Impact of the Intervention on Patient Understanding  
 Patients who met with the Pharmacist and Navigator the initial education and 
teach-back session showed sufficient understanding of taking and handling their OAM. 
During the teach-back, the Pharmacist and Navigator emphasized to the patients that the 
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teach-back questions were not a memory assessment, but rather a way to improve how 
the care team can enhance patients’ knowledge through direct instruction and use of 
prepared tools. Furthermore, having the Medication Navigator check-in at a periodic 
interval served as a helpful way to boost or reinforce patients’ understanding.  
Patients retained much of the same information about medication taking and 
handling about a week after they started, although some patients had difficulty 
remembering (or alternatively, pronouncing) the names of their medications. The high 
rate of retention suggests that the in-person education sessions and teach-helped the 
patients recall and retain the information shared with them longer term, and/or that the 
patients were more familiarized with the tools and more primed to use them at their 
disposal. Additionally, it supports current literature by illustrating that adherence to 
medications can be closely correlated with how well the patients know how to take and 
manage them, and best if augmented with routine follow-up.  
These results further reflect what existing literature has shown in that 
interventions consisting multiple check-ins over a period of team and including a 
combination of different approaches were more successful in promoting patient 
understanding and adherence to their medications. What this study adds is that there can 
be substantial benefit to not only checking-in with patients to remind them to take their 
OAM, but also repeatedly assess and strengthen their knowledge by using educational 
teach-back and weaving supportive tools like the Calendar and Information Sheets into 
these sessions. This could further engage patients into their care and empower them in 
their self-management. However, while this intervention has strived to enhance patient 
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understanding around medication taking and handling, more efforts need to be made in 
clarifying confusion around the logistics of filling/refilling the medications. 
 
Timely Identification and Resolution of Issues 
 We found that patients on OAM identified a variety of issues while taking them, 
and that the planned check-ins with the Pharmacist and/or Navigator created 
opportunities to address them. First, the range of issues related to OAM was striking from 
logistical to clinical. Second, often times these issues were identified by the Pharmacist 
and/or Navigator at the time of the check-ins, suggesting that these may not have been 
brought to the oncology teams’ attention yet. Also, there were more occasions where the 
Navigator contacted the care team on the patients’ behalf than the Pharmacist, which may 
suggest several reasons. First, it could have been that there were more issues raised after 
the patients started on treatment. Second, it could have been that some of the issues 
required the extra clinical expertise of the Pharmacist and other providers to be resolved. 
And third, perhaps having access to the Pharmacist during the check-in could have 
mitigated the need to go straight to the care team.   
That the Pharmacist and Navigator contacted the care team from 32.4% of the 
initial sessions and 60.6% of the booster check-ins regarding many issues  (which were 
often at the time of scheduled clinic visits or in between them) illustrates the potential for 
this intervention to be a safety net for patients and to address their issues in a timely 
manner. This could especially be helpful for patients with more advanced disease and/or 
burdened with other comorbidities, and who may require more care. Furthermore, 
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regularly checking in and interacting with patients fosters rapport between the patients 
and the Pharmacist and Navigator. This allows the patients to feel supported and perhaps 
more inclined to share their concerns. Effective teamwork and rapport between the 
Navigator and Pharmacist also increases efficiency in identifying and resolving patient 
issues.   
 
Analysis on the Usefulness of the Planned Check-Ins and Educational Tools 
 Patients largely responded positively towards the scheduled check-ins with the 
Pharmacist and Navigator, indicating a significant level of buy-in. Several reasons could 
have explained their high degree of acceptability of the intervention. First, the check-ins 
may have served as times when information about their OAM could be explained in 
detail, and any questions and confusion the patients might have had could be addressed. 
This could be especially useful if patients had lingering concerns that were not addressed 
during their clinic visits with their oncologists, especially if time is limited. Second, the 
patients may have considered the Pharmacist and Navigator as additional sources of 
support. They may have viewed them as providers they can go to if they feel they cannot 
contact their primary oncology team or if they feel that their questions were more specific 
to their medications. And finally, patients may have simply appreciated the constant, 
sustained support through these check-ins. As more responsibility was placed on them in 
managing their treatments outside the hospital setting, they may have felt more reassured 
that they knew whom to contact and when to contact them if they had any issues, seeking 
guidance instead of trying to navigate these concerns on their own. 
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Patients also viewed the Information Sheets and Medication Calendars as being 
helpful, although these tools were not used by all patients. Among the users, patients 
appeared to have incorporated them into their own care management. It illustrates that 
rather than simply providing these informational tools for patients, actively using them as 
aids and as part of the educational initiative itself can help patients better understand their 
utility and encourage them to refer to them at home as needed. 
 
Limitations of the Study 
 This study had some limitations. The teach-back in the study asked patients how 
they took their medications, but did not confirm that they had taken them at the right 
frequency (daily and weekly) and the correct dosage. This should be considered in future 
study design since it could be significant for patients with complex dosing schedules and 
to identify more specific gaps in understanding or adherence. Other intervention studies 
and clinical trials have also included the use of electronic monitoring devices (e.g. the 
MEMS caps system) for real-time tracking of pill-taking, and this can be considered in 
future study. Alternatively, pill counts can be taken at each check-in to see if the patients 
are taking the right amount of medications based on the initial dosage dispense. The 
intervention should also be expanded to a greater sample of patients, including a larger 
number of Chinese-speaking patients, to further assess the feasibility of conducting the 
check-ins and delivering language-congruent tools in this and other vulnerable 
populations. As part of this assessment, it could also be worth systematically 
documenting the length of each check-in or visit with the Pharmacist and/or Navigator, 
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and instances where the patient has interacted with either team member in between the 
check-ins. This could further assess workflow requirements and patient/system level 
burden. Adherence was assessed based on patient self-reports. While these were obtained 
with a validated measure, the patients’ actual adherence rates might have still been 
misconstrued and overrated.  
 
Conclusion and Considerations for Future Research 
 This ongoing Pharmacist- and Medication Navigator-led initiative to educate 
patients on their OAM and improve adherence has shown promising results to date. It has 
been feasible to operationalize, effective in enhancing patient understanding, and useful 
in providing continual support for patients. It also offers some insights into implications 
for future work. 
 First, how well patients retain their understanding on their OAM over a longer 
period of time should be investigated. Results gathered from Time 3 and Time 4, check-
ins planned during the Cycle 2 of treatment, may give information on long-term recall. 
Additionally, different questions and challenges might arise, and it could be interesting to 
explore these themes as well as how the intervention might adapt to those. 
 Second, it may be important to acknowledge the role caregivers may play in 
helping patients managing their oral medications. This may especially be helpful for 
patients who have complex treatment regimens alongside other medications to manage 
chronic conditions or symptoms. Caregivers could be invited to attend these check-ins 
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and teach-back sessions with the patients so that they could be adequately informed as 
well. 
 While this intervention aimed to improve understanding and adherence to 
medications through an educational and support initiative, the mechanisms for how 
patients may or may not achieve this can be further explored. One aspect that can be 
studied is the team dynamics between the Pharmacist and Navigator and the duo with the 
oncology clinic team, and how they may facilitate this process. Another theoretical 
pathway to evaluate is to what extent patient’s self-activation and emotional functioning 
can be factors in improving adherence and outcomes, which have been illustrated in other 
chronic conditions, such as diabetes (Shigaki et al. 2010) and cardiovascular conditions 
(Donald et al. 2011). It is possible that regular check-ins and the usage of tools, as forms 
of support, can enhance patients’ self-efficacy in managing their medications. 
Approaching the issues and barriers to OAM adherence through a multifaceted and 
multidisciplinary framework can offer new insight on designing future interventions to 
improve care delivery. 
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